The North Sea's Last Untouched Cousin Now Has a Drill Date.
Forty years of North Sea oil and gas built fortunes for British, Norwegian, and American operators. Across the strait, in onshore east Greenland, sits the same petroleum system — the same Permian-Triassic source rocks, the same reservoir architecture, the same multi-play stacked geology — never properly drilled.
That position is now public. It's called Greenland Energy Company (NASDAQ: GLND).
GLND's updated investor presentation sharpens the picture. The Jameson Land Basin covers more than 8,400 square kilometers of onshore Arctic acreage and is ranked by Sproule as the 13th largest undeveloped oil accumulation in the world. Independent engineering identifies 58 prospects and leads, with up to approximately 13.0 billion barrels of gross un-risked prospective resources.
The deal structure is clean: GLND has rights to earn up to a 70% working interest after funding/completing the first two exploration wells, subject to the farm-out terms.* Each well is drilled to a minimum depth of 3,500 metres — with 80 Mile retaining the residual 30%. The targeted spud window is October 2026. Procurement is underway. Infrastructure mobilization is in motion. Road and pad construction is being planned.
Halliburton is engaged for integrated consulting, logistics, and drilling services. IPT Well Solutions is on project management. Stampede Drilling is contracted to operate. Leadership runs through CEO Robert Price, Chairman Larry Swets, Jr., CFO Ashiq Merchant, Executive Advisor Joe Moglia (former Chairman and CEO of TD Ameritrade), and new Board Director Carol Craig (CEO of Sidus Space).
Layer on the tape — locked-up float, reported borrow rates near ~827% — and the Dr. Phil docuseries hitting 220M+ households in the same window.
The North Sea analog. With a public ticker.
This is a paid advertisement by Greenland Energy Company
*Filings indicate 50% after the first well and 70% after the second.
Sponsored content. Borrow rates and float dynamics fluctuate and should be independently verified. Resource estimates are gross un-risked prospective resources and subject to exploration results. Forward-looking statements involve risks and uncertainties; actual results may differ materially. Not investment advice — consult your financial advisor and review all filings before investing.
Bonus content from Invested Early:
Hello.
Every week, a handful of small caps make a move the headlines skip right past. Our partners AltIndex run their model across ~2,500 stocks, pull the small ones with a real catalyst this week, and show you what the data sees underneath.
Three crossed the radar. Not tips, just early reads.
⚙️ The Elmet Group is buying up the tungsten supply chain
🧬 Regenxbio just got a rare second chance from the FDA
🎮 Corsair is riding the memory boom (and a Reddit wave)
Let’s take a look.
This is not financial advice. Always do your own research. Past performance doesn't guarantee future results.
⚙️ The Elmet Group (ELMT)
Nasdaq | Share Price: ~$18.70 | Market Cap: ~$551M | Critical Minerals
This week: exercised an option to increase its stake in EQ Resources, deepening its bet on tungsten (a critical mineral for defense and electronics), and it's joining the Russell 3000 and Russell Microcap indexes, which forces index funds to buy the stock.
What AltIndex sees: AI Score 54 and two insider purchases in the past 90 days. The stock rose about 3% on the day.
The risk: it's a ~$550M name tied to tungsten prices and defense budgets, and index-inclusion pops can fade once the forced buying is done.
🧬 Regenxbio (RGNX)
Nasdaq | Share Price: ~$10.25 | Market Cap: ~$545M | Gene Therapy
This week: the FDA reversed course and agreed to reconsider Regenxbio's gene therapy for a rare childhood disorder (MPS II) that it rejected just months ago, with no new studies required, and the company finished dosing its Duchenne therapy (RGX-202). Both point to BLA filings in Q3 2026.
What AltIndex sees: AI Score 56, with job postings up 1540% month over month (a hiring ramp the model weighs heavily). Also up about 3% on the day.
The risk: this is clinical-stage biotech. FDA timelines slip, approvals are never guaranteed, and the next binary readout cuts both ways.
🎮 Corsair Gaming (CRSR)
Nasdaq | Share Price: ~$8.80 | Market Cap: ~$926M | Hardware
This week: reports surfaced that Corsair is now using China's CXMT DDR5 memory in some products, a notable move with memory prices surging.
What AltIndex sees: the overall AI Score is a middling 44 and the stock trades around 96 times earnings, so the model is more cautious here than the crowd is.
The risk: this one is sentiment-driven more than fundamentals-driven, and meme momentum reverses fast. The China chip sourcing could also turn into a geopolitical headache.
The bottom line
Three very different shapes of "developing": a defense supplier cornering a critical mineral, a biotech handed a regulatory lifeline, and a hardware brand riding a sentiment wave. The first two have the AltIndex scores to back the story; the third is the crowd running ahead of the data.
None of these are recommendations, and small caps like these can swing 20% on a single headline in either direction. The AI Score is a starting point for your own research, not a verdict. If any earns a spot in your portfolio, make it a small one.
Back next week with three more.
To investing early, The Invested Early team
🫡 See You Soon
That’s all for today’s edition! Watching a name we should cover? Hit reply and tell us.
Cheers,
— Brandon & Blake of Invested Inc.
What did you think of today's edition?
ADVERTISING DISCLOSURES: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) This email is a paid advertisement by Greenland Energy Company and does not constitute investment advice. Invested Inc. has been compensated $5,000 by Greenland Energy Company for the distribution of this profile and related marketing materials. We have not performed due diligence on the company and the information provided is for informational purposes only. We are not a registered investment advisor or broker-dealer.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
The information provided in Invested Early is for informational and educational purposes only and should not be construed as financial advice, investment advice, or a recommendation to buy or sell any securities. Stocks & Income is not a registered investment advisor, broker-dealer, or licensed financial planner. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We may hold positions in or receive compensation from the companies or products mentioned. Disclosures will be made where applicable.
Invested Early, Stocks & Income, AltIndex, Finance Wrapped, The Chain, and Future Funders are all owned by Invested, Inc.
Not financial advice or a recommendation to buy or sell any security. Small and micro-cap stocks are volatile and carry a real risk of loss. All figures sourced from AltIndex as of June 26, 2026. Always do your own research. Invested Early is published by Invested Inc.